Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
29.75
-0.08 (-0.27%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
25,818,849
Open
30.00
Bid (Size)
29.78 (1)
Ask (Size)
29.79 (2)
Prev. Close
29.83
Today's Range
29.73 - 30.14
52wk Range
25.20 - 34.12
Shares Outstanding
5,606,688,356
Dividend Yield
5.51%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
10 Health Care Stocks With Whale Alerts In Today's Session
Today 13:35 EDT
Via
Benzinga
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Today 8:06 EDT
Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity Residential. Moderna has been disappointing, but Cramer likes Vertiv and...
Via
Benzinga
Performance
YTD
+0.07%
+0.07%
1 Month
+3.30%
+3.30%
3 Month
+8.54%
+8.54%
6 Month
+7.67%
+7.67%
1 Year
-11.56%
-11.56%
More News
Read More
3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever
Today 6:57 EDT
Via
The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Today 5:49 EDT
Via
The Motley Fool
Pfizer Unusual Options Activity
September 17, 2024
Via
Benzinga
Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
September 16, 2024
Via
Benzinga
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
September 15, 2024
Via
The Motley Fool
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
September 17, 2024
From
Pfizer Inc.
Via
Business Wire
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Via
The Motley Fool
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
September 17, 2024
Via
Talk Markets
Intel, Microsoft, Meta Platforms, Pfizer, Tesla: Why These 5 Stocks Are On Investors' Radars Today
September 16, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
September 16, 2024
Via
The Motley Fool
Topics
Supply Chain
Exposures
Supply Chain
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
September 16, 2024
Via
Benzinga
Exposures
COVID-19
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
September 16, 2024
Via
Newsfile
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
September 14, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
September 14, 2024
From
Pfizer Inc.
Via
Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
September 13, 2024
Via
Investor's Business Daily
Got $5,000? 3 Dirt Cheap Stocks to Buy Right Now
September 13, 2024
Via
The Motley Fool
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
Via
The Motley Fool
A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
September 13, 2024
Via
The Motley Fool
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
September 12, 2024
Via
MarketBeat
Exposures
Product Safety
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
September 11, 2024
Via
Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
September 11, 2024
Via
Benzinga
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
Via
The Motley Fool
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.